Table 1.
List of rituximab biosimilars around the world including the manufacturer and their corporate location, clinical trial status and for respective disease, status, and cost relative to the rituximab.
| Biosimilar (reference) | Manufacturer | Clinical trials ongoing or completed | Disease | Status | Relativea cost to rituximab; $3,693 (500 mg) (191) |
|---|---|---|---|---|---|
| 1B8 (192, 193) | Center of Molecular Immunology (Cuba) | Phase I | DLCBL | Pharmacokinetics and Safety in Progress | N/A |
| ABP 798 (194, 195) | Amgen (USA) | Phase III | NHL | Recruiting | N/A |
| BCD-020 (Acellbia) (173, 196–198) | Biocad (Russia) | Approved | INHL | Launched | 72% less |
| BI 695500 (167, 168, 170–175, 199) | Boehringer Ingelheim (Germany) | Phase III | LTBFL | Terminated | N/A |
| CT-P10 (Truxima) (177, 200) | Celltrion (South Korea) | Approved | ASFL | Launched | 72% less |
| GP2013 (Rixathon) (201) | Novartis Pharmaceuticals (Switzerland) | Phase III | ASFL | In progress | N/A |
| HLX01 (182) | Shanghai Henlius Biotech (China) | Phase III | DLBCL | In progress | N/A |
| JHL1101 (202, 203) | JHL Biotech (Taiwan) and Sanofi (France) | Phase I and III | NHL | In progress | N/A |
| Kikuzubam (204, 205) | Probiomed (Mexico) | Phase I | NHL | Withdrawn | N/A |
| Maball (206, 207) | Hetero (India) | Approved | CLL, DLCBL, and FL | Launched | 87% less |
| MabionCD20 (208) | Mabion SA (Poland) | Phase III | DLBCL | Recruiting | N/A |
| MabTas (209–211) | Intas Pharmaceuticals (India) | Approved | NHL | Launched | 76% less |
| MK8808 (212) | Merck Sharp & Dohme Corp. (EU) | Phase I | FL | Terminated | N/A |
| Novex (213, 214) | Laboratorio Elea (Argentina) | Approved | NHL | Launched | 9% less |
| PF-05280586 (215) | Pfizer (USA) | Phase III | LTBFL | Recruiting | N/A |
| Reditux (155, 187, 216) | Dr. Reddy’s Laboratories (India) | Approved | DLBCL | Launched | 50% less |
| Rituxirel (217, 218) | Reliance Life Sciences, Torrent Pharma (India) | Approved | NHL (DLBCL and FL) | Launched | 84% less |
| RTXM83 (219) | mAbxience (Switzerland) | Phase III | DLBCL | Completed | N/A |
| SAIT101 (220) | Samsung BioLogics (South Korea) and AstraZeneca (UK) | Phase III | LTBFL | Completed | N/A |
| TL011 (221) | Teva Pharmaceuticals (Israel) | Phase III | DLBCL | Terminated | N/A |
| Zytux (Ristova) (222, 223) | AryoGen Biopharma (Iran) | Approved | NHL | Launched | 50% less |
ASFL, advanced stage follicular lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; INHL, indolent non-Hodgkin lymphoma; LTBFL, low tumor burden follicular lymphoma; NHL, non-Hodgkin lymphoma; EU, European Union.
aPrices vary depending on the market and the country where the product is sold. N/A, not available.